Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages

Journal of Interferon and Cytokine Research

Volumn 28, Issue 4, 2008, Pages 207-219

  Jawa, Randeep S ^a,c   Chattopadhyay, Souvik ^b   Tracy, Erin ^b   Wang, Yanping ^b   Huntoon, Kristin ^b   Dayton, Merril T ^a   Baumann, Heinz ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 31; INTERLEUKIN 31 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; CANCER CELL CULTURE; CARCINOMA CELL; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

BRONCHI; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DEXAMETHASONE; DNA; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; MACROPHAGES, ALVEOLAR; PULMONARY ALVEOLI; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 42549171009     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0057     Document Type: Article

References (39)

1. Bando T, Morikawa Y, Komori T, Senba E. 2006. Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience 142(4):1263-1271.
2. Barthelemy-Brichant N, David JL, Bosquee L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet-Mahieu L, Deneufbourg JM. 2002. Increased TGFbeta1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 32(3):193-198.
3. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H. 2001. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 276(50):47038-47045.
4. Boutten A, Venembre P, Seta N, Hamelin J, Aubier M, Durand G, Dehoux MS. 1998. Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. Am J Respir Cell Mol Biol 18(4):511-520.
5. Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, Graham-Evans B, Ghilardi N, de Sauvage FJ. 2007. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol 35(4 Suppl 1):78-86.
6. Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. 2007. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem 282(5):3014-3026.
7. Cichy J, Rose-John S, Pure E. 1998. Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells. FEBS Lett 429(3):412-416.
8. Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, Brand S. 2007. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56(9):1257-1265.
9. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, and others. 2004. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5(7):752-760.
10. Diveu C, Lak-Hal AH, Froger J, Ravon E, Grimaud L, Barbier F, Hermann J, Gascan H, Chevalier S. 2004. Predominant expression of the long isoform of gp130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 15(4):291-302.
11. Diveu C, Lelievre E, Perret D, Lak-Hal AH, Froger J, Guillet C, Chevalier S, Rousseau F, Wesa A, Preisser L, and others. 2003. GPL, a novel cytokine receptor related to gp130 and leukemia inhibitory factor receptor. J Biol Chem 278(50):49850-49859.
12. Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. 2006. Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp (Warsz) 54(2):143-147.
13. Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermanns HM. 2004. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem 279(34):36112-36120.
14. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. 2005. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 66(2):175-191.
15. Falus A, Taga T, Hibi M, Murakami M, Kishimoto T. 1992. Regulation of IL-6 receptor and gp130 expression on human cell lines of lymphoid and myeloid origin. Cytokine 4(6):495-499.
16. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15(2):142-145.
17. Flanders KC, Burmester JK. 2003. Medical applications of transforming growth factor-beta. Clin Med Res 1(1):13-20.
18. Geisterfer M, Gauldie J. 1996. Regulation of signal transducer, gp130 and the LIF receptor in acute inflammation in vivo. Cytokine 8(4):283-287.
19. Ghilardi N, Li J, Hongo JA, Yi S, Gurney A, de Sauvage FJ. 2002. A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem 277(19):16831-16836.
20. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1-20.
21. Illman SA, Lehti K, Keski-Oja J, Lohi J. 2006. Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18):3856-3865.
22. Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW. 2007. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology 122(4):532-541.
23. Jostock T, Blinn G, Renne C, Kallen KJ, Rose-John S, Mullberg J. 1999. Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. J Immunol Methods 223(2):171-183.
24. Kong FM, Washington MK, Jirtle RL, Anscher MS. 1996. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 16(1):47-59.
25. Kurdi M, Booz GW. 2007. Jak inhibition, but not Stat1 knockdown, blocks the synergistic effect of IFN-γ on Fas-induced apoptosis of A549 human non-small cell lung cancer cells. J Interferon Cytokine Res 27(1):23-31.
26. Li AG, Lu SL, Han G, Hoot KE, Wang XJ. 2006. Role of TGFbeta in skin inflammation and carcinogenesis. Mol Carcinog 45(6):389-396.
27. Loewen GM, Tracy E, Blanchard F, Tan D, Yu J, Raza S, Matsui S, Baumann H. 2005. Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer 5:145.
28. Marek A, Brodzicki J, Liberek A, Korzon M. 2002. TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med Sci Monit 8(7):RA145-151.
29. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC, Merk HF, and others. 2006. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 118(4):930-937.
30. Ouyang L, Shen LY, Li T, Liu J. 2006. Inhibition effect of oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res 27(4):197-202.
31. Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, Pearce EJ, Ghilardi N, Artis D. 2007. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med 204(3):481-487.
32. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. 2005. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65(19):8896-8904.
33. Rakemann T, Niehof M, Kubicka S, Fischer M, Manns MP, Rose-John S, Trautwein C. 1999. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem 274(3):1257-1266.
34. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K. 2002. Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem 277(14):12067-12074.
35. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. 2005. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 516(2):180-181.
36. Van Laethem F, Liang X, Andris F, Urbain J, Vandenbranden M, Ruysschaert JM, Resh MD, Stulnig TM, Leo O. 2003. Glucocorticoids alter the lipid and protein composition of membrane rafts of a murine T cell hybridoma. J Immunol 170(6):2932-2939.
37. Wahl SM. 1994. Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med 180(5):1587-1590.
38. Yagi Y, Andoh A, Nishida A, Shioya M, Nishimura T, Hashimoto T, Tsujikawa T, Saito Y, Fujiyama Y. 2007. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med 19(6):941-946.
39. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. 2007. Anti-beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-3035.